INT250888

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.30
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 6
Disease Relevance 6.13
Pain Relevance 2.15

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (IL23A)
Anatomy Link Frequency
joint 1
Th17 cells 1
IL23A (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 175 100.00 Very High Very High Very High
psoriasis 166 99.44 Very High Very High Very High
rheumatoid arthritis 131 99.02 Very High Very High Very High
cytokine 113 95.32 Very High Very High Very High
Arthritis 44 93.08 High High
Etanercept 52 89.08 High High
chemokine 11 85.52 High High
Onset of action 3 69.68 Quite High
methotrexate 27 65.80 Quite High
antagonist 3 65.16 Quite High
Disease Link Frequency Relevance Heat
INFLAMMATION 167 100.00 Very High Very High Very High
Disease 210 99.88 Very High Very High Very High
Psoriasis 205 99.44 Very High Very High Very High
Rheumatoid Arthritis 132 99.02 Very High Very High Very High
Cancer 60 93.80 High High
Necrosis 8 93.56 High High
Seronegative Spondarthritis 40 93.08 High High
Body Weight 6 89.96 High High
Colitis 18 89.76 High High
Inflammatory Bowel Disease 115 89.60 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In contrast, other mutations that decrease IL-23 or IL-12 will give protection from psoriasis.27–29 Altogether, these findings indicate that genes participating in IL-12/23 signaling play a significant role in the pathogenesis of chronic epithelial inflammation as seen in psoriasis.
Negative_regulation (decrease) of IL-23 associated with psoriasis and inflammation
1) Confidence 0.30 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2857612 Disease Relevance 1.08 Pain Relevance 0.48
As a newly developed, targeted biological agent, ustekinumab has demonstrated superior efficacy and safety in the treatment of plaque psoriasis by its unique mechanism of inhibiting IL-12/23 inflammatory pathways.7 IL-23 stimulates survival and proliferation of Th17 cells, a key cell that regulates the production of other inflammatory cytokines (IL-17, IL-22, IL-21, IL-6, tumor necrosis factor (TNF)-?)
Negative_regulation (inhibiting) of IL-23 in Th17 cells associated with psoriasis, necrosis, inflammation, cancer and cytokine
2) Confidence 0.22 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2857612 Disease Relevance 1.11 Pain Relevance 0.61
Symptoms gradually recurred in patients who therapy was withdrawn and quality of life improvements were lost, indicting the block of IL-12 and IL-23 is temporary and does not reverse the underlying causal mechanism of psoriasis.
Negative_regulation (block) of IL-23 associated with psoriasis
3) Confidence 0.22 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2857612 Disease Relevance 0.72 Pain Relevance 0.19
Further, in the RA joint, CD4+ cells may be more responsive to low levels of IL-23, especially in an environment rich in IL-1?
Negative_regulation (levels) of IL-23 in joint associated with rheumatoid arthritis
4) Confidence 0.19 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2575607 Disease Relevance 0.97 Pain Relevance 0.44
Genome-wide association studies have linked CD to a number of IL-23 pathway genes, including the encoding gene for IL-23 Receptor.
Negative_regulation (number) of IL-23 associated with disease
5) Confidence 0.11 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2821644 Disease Relevance 1.21 Pain Relevance 0.20
Of note, the IL-23 receptor gene was recently associated with Crohn’s disease; namely, polymorphisms in this gene appear to confer protection against the disease.84 This would suggest that agents that inhibit IL-23 may prove to be effective in Crohn’s disease.
Negative_regulation (inhibit) of IL-23 associated with disease
6) Confidence 0.06 Published 2007 Journal J Gastroenterol Section Body Doc Link PMC2780674 Disease Relevance 1.04 Pain Relevance 0.21

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox